Abstract
Although statins are widely used as cholesterol-lowering drugs, a recent study suggests that these compounds have anabolic effects on bone and could be developed into new treatments for common metabolic bone diseases such as osteoporosis
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1
Lipids in Health and Disease Open Access 02 June 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mundy, G. et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946– 1949 (1999).
Alberts, A.W. et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. USA 77, 3957–3961 ( 1980).
Hamelin, B.A. & Turgeon, J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors . Trends Pharmacol. Sci. 19, 26– 37 (1998).
Zhang, F.L. & Casey, P.J. Protein prenylation: molecular mechanisms and functional consequences. Ann. Rev. Biochem. 65, 241–269 (1996).
Garrett, I.R., Escobedo, A. & Mundy, G.R. N2-containing bisphosphonates risedronate and ibandronate stimulate bone formation in organ culture. J. Bone Miner. Res. 14 S525 (abstract) (1999).
Luckman, S.P. et al. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13, 58 –589 (1998).
Fisher, J.E. et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc. Natl. Acad. Sci. USA 96, 133–138 ( 1999).
van Beek, E. et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 264, 108–111 ( 1999).
Plotkin, L.I. et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 104, 1363 –1374 (1999).
Bauer, D.C. et al. Statin use, bone mass and fracture: an analysis of two prospective studies. J. Bone Miner. Res. 14, S179 (abstract) (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rogers, M. Statins: lower lipids and better bones?. Nat Med 6, 21–23 (2000). https://doi.org/10.1038/71484
Issue Date:
DOI: https://doi.org/10.1038/71484
